Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
p65 siRNA
- Development stage
- Preclinical
- Lead developer
- Cell Signaling Technology
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Intratumoral, Intraarticular
01
Overview
p65 siRNA is a small interfering RNA (siRNA) designed to silence the expression of the p65 (RelA) subunit of the NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) transcription factor. By utilizing the RNA interference (RNAi) pathway, it leads to the sequence-specific degradation of p65 mRNA, thereby reducing the levels of the p65 protein. This suppression inhibits the activation of the NF-κB signaling pathway, which is a central regulator of inflammatory responses, immune cell activation, and cell survival. In preclinical research, p65 siRNA has been explored as a potential therapeutic for various inflammatory diseases, such as rheumatoid arthritis and acute lung injury, as well as cancers like glioblastoma and colon cancer. It is frequently studied in conjunction with specialized delivery systems, including lipid nanoparticles, micelles, and DNA nanostructures, to overcome the challenges of oligonucleotide delivery.
- Brand names
- SignalSilence NF-κB p65 siRNA
- Other names
- RelA siRNANF-κB p65 siRNAp65 small interfering RNAp-65 small interfering RNAp 65 small interfering RNA
02
Targets
RELA (Nuclear Factor Kappa B Subunit p65)
Beyond the preview
Go deeper on p65 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on p65 siRNA.